Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy
Authors:
- Marilyn H. BoydenMBMarilyn H. Boyden
- Lee Ann GallantLGLee Ann Gallant
- Holly CarleyHCHolly Carley
- Melvin H. FreedmanMFMelvin H. Freedman
- 1 December 1987
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 83 (6) , 1085-1090
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects.BMJ, 1985
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- OCULAR TOXICITY OF DESFERRIOXAMINEThe Lancet, 1985
- Depletion of excessive liver iron stores with desferrioxamineBritish Journal of Haematology, 1984
- Deferoxamine (Desferal®)-induced Toxic Retinal Pigmentary Degeneration and Presumed Optic NeuropathyOphthalmology, 1984
- VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1984
- DESFERRIOXAMINE, OCULAR TOXICITY, AND TRACE METALSThe Lancet, 1983
- OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINEThe Lancet, 1983
- Response to long-term deferoxamine therapy in thalassemiaThe Journal of Pediatrics, 1981